Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
All content for Beyond the Endpoint is the property of Duke Clinical Research Institute and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
Bridging Science and Policy: A Conversation with Dr. Robert Califf
Beyond the Endpoint
31 minutes 7 seconds
7 months ago
Bridging Science and Policy: A Conversation with Dr. Robert Califf
In this episode of Beyond the Endpoint, former FDA commissioner Dr. Robert Califf joins hosts Manesh Patel and Emily O’Brien to discuss critical challenges shaping the future of patient care. From misinformation to regulatory science to the financialization of healthcare, Dr. Califf has unique insight into the evolving healthcare landscape and the role of data in improving patient outcomes.
🔗 Access resources related to this episode https://dcri.org/blog/ep-6-bridging-science-and-policy-conversation-dr-robert-califf
Beyond the Endpoint
Endocrinologist Jennifer Green discusses how GLP-1 drugs, like Ozempic, evolved from diabetes tools to potential treatments for addiction and heart disease, in this final installment of the obesity series. The discussion also touches on critical questions about long-term use, access, and emerging innovations.
